BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC – Get Free Report) insider Xiaodong Wang sold 31,027 shares of the company’s stock in a transaction dated Tuesday, October 13th. The shares were sold at an average price of $350.99, for a total value of $10,890,166.73. Following the completion of the transaction, the insider owned 31,027 shares in the company, valued at $10,890,166.73. This represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Xiaodong Wang also recently made the following trade(s):
- On Monday, September 28th, Xiaodong Wang sold 31,028 shares of BeOne Medicines stock. The stock was sold at an average price of $364.79, for a total transaction of $11,318,704.12.
- On Tuesday, September 8th, Xiaodong Wang sold 38,287 shares of BeOne Medicines stock. The stock was sold at an average price of $349.10, for a total value of $13,365,991.70.
BeOne Medicines Price Performance
Shares of ONC opened at $369.06 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. The firm has a market cap of $40.52 billion, a PE ratio of 65.86 and a beta of 0.61. BeOne Medicines Ltd. – Sponsored ADR has a twelve month low of $253.95 and a twelve month high of $385.22. The firm’s 50 day moving average price is $360.42 and its 200 day moving average price is $321.65.
BeOne Medicines (NASDAQ:ONC – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%. The business had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. As a group, research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 EPS for the current fiscal year.
Hedge Funds Weigh In On BeOne Medicines
Hedge funds have recently added to or reduced their stakes in the stock. Mather Group LLC. grew its holdings in shares of BeOne Medicines by 192.0% in the 3rd quarter. Mather Group LLC. now owns 73 shares of the company’s stock valued at $27,000 after buying an additional 48 shares during the period. GAMMA Investing LLC raised its holdings in BeOne Medicines by 39.5% during the 3rd quarter. GAMMA Investing LLC now owns 120 shares of the company’s stock worth $44,000 after buying an additional 34 shares during the period. Parallel Advisors LLC lifted its position in BeOne Medicines by 24.0% in the 1st quarter. Parallel Advisors LLC now owns 351 shares of the company’s stock valued at $104,000 after acquiring an additional 68 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of BeOne Medicines by 16.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 369 shares of the company’s stock valued at $110,000 after purchasing an additional 52 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of BeOne Medicines in the first quarter valued at about $201,000. Institutional investors and hedge funds own 48.55% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on ONC shares. Wall Street Zen upgraded shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 18th. Royal Bank Of Canada upped their target price on shares of BeOne Medicines from $450.00 to $459.00 and gave the stock an “outperform” rating in a report on Thursday, October 8th. Morgan Stanley reiterated an “overweight” rating and set a $425.00 target price on shares of BeOne Medicines in a research report on Friday. Citizens Jmp raised their price objective on shares of BeOne Medicines from $396.00 to $405.00 and gave the stock a “market outperform” rating in a report on Thursday, August 6th. Finally, Nomura raised BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, BeOne Medicines currently has a consensus rating of “Buy” and a consensus target price of $407.07.
Get Our Latest Research Report on ONC
About BeOne Medicines
BeOne Medicines Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors.
Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers.
Featured Stories
- Five stocks we like better than BeOne Medicines
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for BeOne Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeOne Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
